Advertisement
Screener

MUSTANG BIO, INC. (MBIO) Net Cash Provided by (Used in) Investing Activities, Continuing Operations

MUSTANG BIO, INC. Net Cash Provided by (Used in) Investing Activities, Continuing Operations

MUSTANG BIO, INC. (MBIO) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of -$20.61 million for the 6-month period ending 2017-06-30, per its 10-Q filed 2017-08-14.

Discontinued › Cash Flow › Investing Activities

us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2017-08-14

  • MUSTANG BIO, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-06-30 was -$20.24M.
  • MUSTANG BIO, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-03-31 was -$375.00K.
  • MUSTANG BIO, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-12-31 was $0.00.
  • MUSTANG BIO, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-09-30 was $0.00.
  • MUSTANG BIO, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2016 was $0.00.
Period endNet Cash Provided by (Used in) Investing Activities, Continuing Operations 3 monthNet Cash Provided by (Used in) Investing Activities, Continuing Operations 6 monthNet Cash Provided by (Used in) Investing Activities, Continuing Operations 7 monthNet Cash Provided by (Used in) Investing Activities, Continuing Operations 9 monthNet Cash Provided by (Used in) Investing Activities, Continuing Operations 10 monthNet Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month
2017-06-30-$20.24M
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-14
-$20.61M
10-Q · filed 2017-08-14
-$20.61M
derived: sum of 3 quarters · filed 2017-08-14
-$20.61M
derived: sum of 4 quarters · filed 2017-08-14
2017-03-31-$375.00K
10-Q · filed 2017-05-15
-$375.00K
derived: sum of 2 quarters · filed 2017-05-15
-$375.00K
derived: sum of 3 quarters · filed 2017-05-15
-$375.00K
derived: sum of 4 quarters · filed 2017-08-14
2016-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-31
$0.00
derived: sum of 2 quarters · filed 2017-03-31
$0.00
derived: sum of 3 quarters · filed 2017-08-14
$0.00
10-K · filed 2017-03-31
2016-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-14
$0.00
derived: sum of 2 quarters · filed 2017-08-14
$0.00
10-Q · filed 2016-11-14
2016-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-14
$0.00
10-Q · filed 2017-08-14
2016-03-31$0.00
10-Q · filed 2017-05-15
2015-12-31-$2.00M
10-K · filed 2017-03-31
2015-09-30-$2.00M
10-Q · filed 2016-11-14

Similar stocks

Stock NameCountryMarket CapPE Ratio
Vistagen Therapeutics, Inc. (VTGN)United States$0.013B-0.14
AEON Biopharma, Inc. (AEON)United States$0.013B-0.36
LISATA THERAPEUTICS, INC. (LSTA)United States$0.014B-2.13
Tempest Therapeutics, Inc. (TPST)United States$0.013B
Aspire Biopharma Holdings, Inc. (ASBP)United States$0.012B-0.60
BIOVIE INC. (BIVI)United States$0.012B
BullFrog AI Holdings, Inc. (BFRG)United States$0.014B
ADIAL PHARMACEUTICALS, INC. (ADIL)United States$0.012B
Vyome Holdings, Inc (HIND)United States$0.014B-1.38
Tvardi Therapeutics, Inc. (TVRD)United States$0.014B